US Patent Issued to McNeil on July 21 for "Biomarker based nicotine replacement therapy" (Pennsylvania, New Jersey Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,688,916, issued on July 21, was assigned to McNeil AB (Helsingborg, Sweden).

"Biomarker based nicotine replacement therapy" was invented by Justin Mellinger (Philadelphia), Ryan Walsh (Downingtown, Pa.), Sophie Edgar (Hoboken, N.J.), Ming Dong (Hoboken, N.J.) and Curt Binner (Furlong, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A device for providing nicotine replacement therapy may be provided. The device may comprise a processor. The processor may be configured to perform one or more actions. A cessation program for a user may be determined. A program intervention event based on a phase of the cessation program may be determined. A marker assoc...